dough
@semodough
BIOTECH man LONGTERM FOCUS many positions-also trade around my CORE holdings my opinion only do your own research with me
Joined September 2015
646 Following 44.4K Followers
$VKTX Baird who don’t even cover it -Viking making the
case as potentially becoming the Least-Frequent Doser. Viking generated the biggest near-term excitement
with maintenance data from the GLP-1/GIP receptor agonist, VK2735, which showed patients retained up to
97% of prior weight loss for 3 months on every-other-week dosing and up to 90% on monthly dosing for 3
months after an initial weekly-treatment period
Show more
